Sukumar Pal1, Alison Favaroni2, Delia F Tifrea1, Philipp T Hanisch2, Sören E T Luczak2, Johannes H Hegemann2, Luis M de la Maza3. 1. Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, USA. 2. Institut für Funktionelle Genomforschung der Mikroorganismen, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. 3. Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, USA. Electronic address: lmdelama@uci.edu.
Abstract
OBJECTIVES: To test vaccines, formulated with novel antigens, to protect mice against Chlamydia infections. METHODS: To determine the ability of polymorphic membrane proteins (Pmps) to induce cross-species protective immune responses, recombinant fragments from all nine C. trachomatis serovar E Pmps were used to vaccinate BALB/c mice utilizing CpG-1826 and Montanide ISA 720 as adjuvants. C. muridarum recombinant MOMP and PBS, formulated with the same adjuvants, were used as positive and negative controls, respectively. Mice were challenged intranasally with 104 inclusion-forming units (IFU) of C. muridarum. Animals were weighed daily and at 10days post-challenge, they were euthanized, their lungs harvested, weighed and the number of chlamydial IFU counted. RESULTS: Following vaccination the nine Pmps elicited immune responses. Based on body weight changes, or number of IFU recovered from lungs, mice vaccinated with Pmp C, G or H were the best protected. For example, over the 10-day period, the negative control group vaccinated with PBS lost significantly more body weight than mice immunized with PmpC or G (P<0.05). C. muridarum MOMP vaccinated mice were better protected against body weight losses than any group immunized with Pmps. Also, the median number of IFU recovered from the lungs of mice vaccinated with PmpC (72×106) or PmpH (61×106) was significantly less than from mice immunized with PBS (620×106; P<0.05). As determined by the number of IFU, all Pmps elicited less protection than C. muridarum MOMP (0.078×106 IFU; P<0.05). CONCLUSIONS: This is the first time PmpC has been shown to elicit cross-species protection against a respiratory challenge. Additional work with Pmps C, G and H is recommended to determine their ability to protect animal models against genital and ocular challenges.
OBJECTIVES: To test vaccines, formulated with novel antigens, to protect mice against Chlamydia infections. METHODS: To determine the ability of polymorphic membrane proteins (Pmps) to induce cross-species protective immune responses, recombinant fragments from all nine C. trachomatis serovar E Pmps were used to vaccinate BALB/c mice utilizing CpG-1826 and Montanide ISA 720 as adjuvants. C. muridarum recombinant MOMP and PBS, formulated with the same adjuvants, were used as positive and negative controls, respectively. Mice were challenged intranasally with 104 inclusion-forming units (IFU) of C. muridarum. Animals were weighed daily and at 10days post-challenge, they were euthanized, their lungs harvested, weighed and the number of chlamydial IFU counted. RESULTS: Following vaccination the nine Pmps elicited immune responses. Based on body weight changes, or number of IFU recovered from lungs, mice vaccinated with Pmp C, G or H were the best protected. For example, over the 10-day period, the negative control group vaccinated with PBS lost significantly more body weight than mice immunized with PmpC or G (P<0.05). C. muridarum MOMP vaccinated mice were better protected against body weight losses than any group immunized with Pmps. Also, the median number of IFU recovered from the lungs of mice vaccinated with PmpC (72×106) or PmpH (61×106) was significantly less than from mice immunized with PBS (620×106; P<0.05). As determined by the number of IFU, all Pmps elicited less protection than C. muridarum MOMP (0.078×106 IFU; P<0.05). CONCLUSIONS: This is the first time PmpC has been shown to elicit cross-species protection against a respiratory challenge. Additional work with Pmps C, G and H is recommended to determine their ability to protect animal models against genital and ocular challenges.
Authors: Roberta B Ness; Kenneth J Smith; Chung-Chou H Chang; Enrique F Schisterman; Debra C Bass Journal: Sex Transm Dis Date: 2006-03 Impact factor: 2.830
Authors: Delia F Tifrea; Guifeng Sun; Sukumar Pal; Gustavo Zardeneta; Melanie J Cocco; Jean-Luc Popot; Luis M de la Maza Journal: Vaccine Date: 2011-05-06 Impact factor: 3.641
Authors: Deborah D Crane; John H Carlson; Elizabeth R Fischer; Patrik Bavoil; Ru-ching Hsia; Chun Tan; Cho-chou Kuo; Harlan D Caldwell Journal: Proc Natl Acad Sci U S A Date: 2006-01-30 Impact factor: 11.205
Authors: Maria I Cruz-Fisher; Chunmei Cheng; Guifeng Sun; Sukumar Pal; Andy Teng; Douglas M Molina; Matthew A Kayala; Adam Vigil; Pierre Baldi; Philip L Felgner; Xiaowu Liang; Luis M de la Maza Journal: Infect Immun Date: 2010-10-18 Impact factor: 3.441
Authors: Brandie D Taylor; Toni Darville; Chun Tan; Patrik M Bavoil; Roberta B Ness; Catherine L Haggerty Journal: Infect Dis Obstet Gynecol Date: 2011-10-19
Authors: Yibing Wang; Scott D LaBrie; Steven J Carrell; Robert J Suchland; Zoe E Dimond; Forrest Kwong; Daniel D Rockey; P Scott Hefty; Kevin Hybiske Journal: J Bacteriol Date: 2019-11-05 Impact factor: 3.490
Authors: Alison Favaroni; Alexander Trinks; Michael Weber; Johannes H Hegemann; Christiane Schnee Journal: Front Microbiol Date: 2021-03-29 Impact factor: 5.640
Authors: Abisola Abisoye-Ogunniyan; Isabella M Carrano; Dina R Weilhammer; Sean F Gilmore; Nicholas O Fischer; Sukumar Pal; Luis M de la Maza; Matthew A Coleman; Amy Rasley Journal: Front Pharmacol Date: 2021-11-24 Impact factor: 5.988
Authors: Christian Lanfermann; Sebastian Wintgens; Thomas Ebensen; Martin Kohn; Robert Laudeley; Kai Schulze; Claudia Rheinheimer; Johannes H Hegemann; Carlos Alberto Guzmán; Andreas Klos Journal: Vaccines (Basel) Date: 2021-06-06